United States - English - NLM (National Library of Medicine)

rotop pharmaka gmbh - 2,3-dimercaptosuccinic acid (unii: 4s9ju7xf01) (2,3-dimercaptosuccinic acid - unii:4s9ju7xf01) - 2,3-dimercaptosuccinic acid 1 mg - rotop - dmsa is a radiodiagnostic pharmaceutical. the kit contains the non-radioactive powder for reconstitution of the [99m tc]technetium succimer injection solution ([99m tc]-dmsa). the sodium [99m t]pertechnetat which is needed for the preparation is not part of this kit. after labelling with sodium [99m tc]technetium pertechnetat solution, rotop - dmsa is used for static renal scintigraphy when adequate diagnostics are not possible using other diagnostic procedures (such as ultrasound): - to identify focal renal parenchymal changes (e.g. in the case of renal infarction) - to identify norm variants such as atypical double kidney, small kidney, dysplastic kidney, horseshoe kidney, as well as to identify ectopic kidneys - to confirm absence of renal function in multicystic kidneys. take special care with rotop – dmsa rotop - dmsa is not suitable for determining global renal function from the dmsa accumulation. in the case of proximal tubulopathies [99m tc]dmsa does not lead to a sufficient diagnostic renal a

Ireland - English - HPRA (Health Products Regulatory Authority)

rotop pharmaka gmbh - mertiatide - kit for radiopharmaceutical preparation - 0.2 milligram(s) - technetium (99mtc) compounds; technetium (99mtc) mertiatide

United States - English - NLM (National Library of Medicine)

leo pharma inc - tacrolimus (unii: wm0haq4wnm) (tacrolimus anhydrous - unii:y5l2157c4j) - tacrolimus anhydrous 0.3 mg in 1 g - protopic® ointment, both 0.03% and 0.1% for adults, and only 0.03% for children aged 2 to 15 years, is indicated as second-line therapy  for the short-term and non-continuous chronic treatment of moderate to severe atopic dermatitis in non-immunocompromised adults and children who have failed to respond adequately to other topical prescription treatments for atopic dermatitis, or when those treatments are not advisable. protopic® ointment is not indicated for children younger than 2 years of age (see boxed warning, warnings and precautions: pediatric use). protopic® ointment is contraindicated in patients with a history of hypersensitivity to tacrolimus or any other component of the ointment.

United States - English - NLM (National Library of Medicine)

astellas pharma us inc. - tacrolimus (unii: wm0haq4wnm) (tacrolimus anhydrous - unii:y5l2157c4j) - tacrolimus 0.3 mg in 1 g - protopic ointment, both 0.03% and 0.1% for adults, and only 0.03% for children aged 2 to 15 years, is indicated as second-line therapy  for the short-term and non-continuous chronic treatment of moderate to severe atopic dermatitis in non-immunocompromised adults and children who have failed to respond adequately to other topical prescription treatments for atopic dermatitis, or when those treatments are not advisable. protopic ointment is not indicated for children younger than 2 years of age (see boxed warning, warnings and precautions: pediatric use). protopic (tacrolimus) ointment is contraindicated in patients with a history of hypersensitivity to tacrolimus or any other component of the ointment.

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

rotop pharmaka gmbh - tetrofosmin (bis)tetrafluoroborate 0,34 mg - eq. tetrofosmin 0,23 mg - kit for radiopharmaceutical preparation - 0,23 mg - tetrofosmin (bis)tetrafluoroborate 0.34 mg - technetium (99mtc) tetrofosmin

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - tacrolimus (unii: wm0haq4wnm) (tacrolimus - unii:wm0haq4wnm) - tacrolimus 1 mg in 1 g - protopic ointment, both 0.03% and 0.1% for adults, and only 0.03% for children aged 2 to 15 years, is indicated as second-line therapy  for the short-term and non-continuous chronic treatment of moderate to severe atopic dermatitis in non-immunocompromised adults and children who have failed to respond adequately to other topical prescription treatments for atopic dermatitis, or when those treatments are not advisable. protopic ointment is not indicated for children younger than 2 years of age (see boxed warning, warnings and precautions: pediatric use). protopic (tacrolimus) ointment is contraindicated in patients with a history of hypersensitivity to tacrolimus or any other component of the ointment.

Israel - English - Ministry of Health

dexcel ltd, israel - tacrolimus - ointment - tacrolimus 0.03 %w/w - tacrolimus - tacrolimus - -treatment of moderate to severe atopic dermatitis in adults who are not adequately responsive to or are intolerant of conventional therapies.-treatment of moderate to severe atopic dermatitis in children (2 years of age and above) who are not adequately responsive to or are intolerant of conventional therapies.-maintenance treatment of moderate to severe atopic dermatitis for the prevention of flares and the prolongation of flare-free intervals in patients experiencing a high frequency of disease exacerbations (i.e. occurring 4 or more times per year) who have had an initial response to a maximum of 6 weeks treatment of twice daily tacrolimus ointment (lesions cleared, almost cleared or mildly affected).

Israel - English - Ministry of Health

dexcel ltd, israel - tacrolimus - ointment - tacrolimus 0.1 %w/w - tacrolimus - tacrolimus - treatment of moderate to severe atopic dermatitis in adults who are not adequately responsive to or are intolerant of conventional therapies.maintenance treatment of moderate to severe atopic dermatitis for the prevention of flares and the prolongation of flare-free intervals in patients experiencing a high frequency of disease exacerbations (i.e. occurring 4 or more times per year) who have had an initial response to a maximum of 6 weeks treatment of twice daily tacrolimus ointment (lesions cleared, almost cleared or mildly affected).

European Union - English - EMA (European Medicines Agency)

leo pharma a/s - tacrolimus - dermatitis, atopic - other dermatological preparations - flare treatmentadults and adolescents (16 years of age and above)treatment of moderate to severe atopic dermatitis in adults who are not adequately responsive to or are intolerant of conventional therapies such as topical corticosteroids.children (two years of age and above)treatment of moderate to severe atopic dermatitis in children (two years of age and above) who failed to respond adequately to conventional therapies such as topical corticosteroids.maintenance treatmentmaintenance treatment of moderate to severe atopic dermatitis for the prevention of flares and the prolongation of flare-free intervals in patients experiencing a high frequency of disease exacerbations (i.e. occurring four or more times per year) who have had an initial response to a maximum of six weeks treatment of twice daily tacrolimus ointment (lesions cleared, almost cleared or mildly affected).

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

rotop pharmaka gmbh - mercaptoacetyltriglycine mertiatide - eq. mertiatide 0,2 mg - kit for radiopharmaceutical preparation - 0,2 mg - mercaptoacetyltriglycine mertiatide - technetium (99mtc) mertiatide